article thumbnail

How single-use technologies can improve antibodies production  

Drug Discovery World

Where the bottlenecks of achieving higher cell density and higher titers were once thought to be issues of the past, hurdles have now shifted to achieving speed and scale in mAb production without sacrificing quality. DC: Antibodies have and remain a large product class within the biopharmaceutical market.

article thumbnail

Webinar: Environmental monitoring within biotherapeutic production

Drug Discovery World

Microbial control within biopharmaceutical manufacturing is a critical quality control to help ensure drug products are free from viable microorganisms. The post Webinar: Environmental monitoring within biotherapeutic production appeared first on Drug Discovery World (DDW).

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

Webinar: Understand microbial control in biotherapy production

Drug Discovery World

Microbial control within biopharmaceutical manufacturing is a critical quality control to help ensure drug products are free from viable microorganisms. The post Webinar: Understand microbial control in biotherapy production appeared first on Drug Discovery World (DDW).

article thumbnail

AI (Artificial Intelligence) Powered Product People

Perficient: Drug Development

AI (Artificial Intelligence) Powered Product People Have you ever wondered how artificial intelligence can transform not only our lives but also our professions? As someone passionate about technology and digital product development, I have always been intrigued by new tools and how they can improve our lives and careers.

article thumbnail

Advancements in upstream CLD for enhanced biotherapeutics production

Drug Discovery World

A complex journey Biotherapeutics discovery and development upstream encounters challenges in cell line development (CLD), clone screening and characterisation, scale up, and eventually production. Stable clonal cell banks are used for GMP production of the final drug product. Metab Eng 2020;57:203.

article thumbnail

Pioneering access to complex generic products 

Drug Discovery World

Claire D’Abreau-Hayling, Chief Scientific Officer at Sandoz, examines how generic products can relieve industry pressure and improve access to essential medicines. Off-patent medicines today account for about 80% of global prescriptions at an estimated 20% of the total cost. Complex generics comprise a diverse range of products.

article thumbnail

Unlocking the potential of natural products in drug discovery

Drug Target Review

Between 2000 and 2020, approximately 30 percent of the newly introduced small molecule drugs were derived from natural products. In recent decades there has been a decline in interest in natural products for drug discovery, with the industry gravitating towards screening libraries of synthetic molecules with predefined chemistries.